Eric Ostertag, MD, PhD, Recounts His Journey from Penn Grad to Poseida CEO on “Close to the Edge”


Ostertag explained how and why Poseida came to focus on cancer and genetic diseases. He also discussed Poseida’s recently-launched collaboration with Takeda Pharmaceutical, in which it agreed to apply Poseida’s technologies to develop up to eight nonviral, in vivo gene therapies, including a Hemophilia A candidate already under development. The collaboration could generate more than $3.6 billion for San Diego-based Poseida . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articleResearchers Uncover What Causes Stress to Give the Red Light to Cell Division
Next articleAncient Genomes and Proteomes Help Uncover Unexpected Origins and Cultural Connections